NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Fate Therapeutics, Inc. FATE
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$6.6M
▼ 51.2% vs FY2024
EPS · FY25
$-1.15
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-51.8%
Net margin · FY25
-2051.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 6.6M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 2051 cents on every revenue dollar this year.
Per share
USD -1.15
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-51.8%
Return on equity, FY2025
ROE
Operating margin-2222.4%
Net margin-2051.1%
Return on assets-35.9%
Each USD of equity lost 52 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−26.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−59.0%
−26.7%
+10.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.12B
Shares outstanding, FY2025
Change, 5 years+31.5%
Change, 10 years+301.7%
The share count grew 32% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 318.9M
total assets, end of FY2025
Total assetsUSD 318.9M
EquityUSD 207.2M
CashUSD 46.6M
Current ratio5.79×
Equity funds 65% of total assets.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.0
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
·
0.0
0.0
0.0
·
·
·
Operating income $B
−0.1
−0.2
−0.2
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.1
−0.2
−0.2
−0.3
−0.2
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
·
·
Net income $B
−0.1
−0.2
−0.2
−0.3
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.15
−1.64
−1.64
−2.91
−2.24
−2.10
−1.44
−1.19
−1.02
−1.05
−1.18
−1.27
−3.54
−13.06
−16.16
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−51.8
−54.2
−37.8
−48.5
−39.9
−55.1
−48.4
−56.0
−57.1
−60.2
−90.4
−65.4
·
·
·
·
·
·
Shares out B
0.12
0.11
0.10
0.10
0.10
0.09
0.08
0.06
0.05
0.04
0.03
0.02
0.02
0.00
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
43 of 43
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed